The important signal for software is not one company’s miss, but a reset in how the market prices durability. When large-cap SaaS names guide cautiously, the multiple effect tends to hit the whole complex first, then the earnings revisions follow 1-2 quarters later; that is especially true for European software where valuation support depends on stable retention and low churn. For INTU, the read-through is more about SMB spending elasticity than direct competition: if budgets are tightening, the market will lower its willingness to pay for even high-quality compounders before the fundamentals visibly break.

Applied Nutrition looks like a momentum winner, but the second-order risk is channel saturation rather than demand collapse. Fast revenue growth tends to invite retailer restocking, promos, and margin normalization within 1-3 quarters; if gross margin or inventory turns slip, the stock can give back a large share of the initial rerating. The main beneficiary may be the retailer/distributor ecosystem, not necessarily other supplement brands, unless category growth is broad-based.

Salmar’s move is more a short-covering signal than a durable change in fundamentals. Salmon is still a spot-price and biology business, so broker upgrades have limited power unless they coincide with tight supply, better feed economics, or a weaker NOK; otherwise the rally can fade quickly if pricing normalizes. Contrarian take: the market may be overreading a few strong prints in low-growth consumer niches while underestimating how quickly those same names mean-revert when volume growth slows or supply responds.